<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: It is not clear why only a minority of patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) develop <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesized that differences among individuals in molecular pathways activated when esophageal squamous epithelium is exposed to reflux underlie the development of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We used esophageal squamous cell lines from patients who had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (<z:mpath ids='MPATH_458'>normal</z:mpath> esophageal squamous [NES]-B3T and NES-B10T) and without <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (NES-G2T and NES-G4T) to study effects of acid and <z:chebi fb="0" ids="22868">bile salts</z:chebi> on expression of the CDX2 gene </plain></SENT>
<SENT sid="3" pm="."><plain>Bay 11-705, Ad5 inhibitor kappaB(IkappaB)alpha-SR, and site-directed mutagenesis were used to explore effects of nuclear factor-kappaB (NF-kappaB) inhibition on CDX2 promoter activity; DNA binding of the NF-kappaB subunits p50 and p65 was assessed by chromatin immune-precipitation </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Acid and <z:chebi fb="0" ids="22868">bile salts</z:chebi> increased CDX2 <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> (<z:chebi fb="2" ids="33699">mRNA</z:chebi>), protein, and promoter activity in NES-B3T and NES-B10T cells, but not in NES-G2T or NES-G4T cells </plain></SENT>
<SENT sid="5" pm="."><plain>Inhibition of NF-kappaB abolished the increase in CDX2 promoter activity </plain></SENT>
<SENT sid="6" pm="."><plain>Increased CDX2 promoter activity was associated with nuclear translocation of p50, which bound to the promoter </plain></SENT>
<SENT sid="7" pm="."><plain>We found CDX2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> in 7 of 10 esophageal squamous biopsy specimens from patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, but in only 1 of 10 such specimens from patients who had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> without <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Acid and <z:chebi fb="0" ids="22868">bile salts</z:chebi> induce CDX2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression in esophageal squamous cells from patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, but not from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> patients without <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>We speculate that these differences in acid- and <z:chebi fb="0" ids="3098">bile salt</z:chebi>-induced activation of molecular pathways may underlie the development of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> </plain></SENT>
</text></document>